Search results for " infectious disease"

showing 10 items of 167 documents

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

2021

Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231…

MaleVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERinfectious diseases0302 clinical medicine030202 anesthesiologyAnesthesiologyCirugía80 and overProspective StudiesYoung adultChildLungAged 80 and overCOVID-19 ; delay ; SARS-CoV-2 ; surgery ; timingSARS‐CoV‐2 infectionOperativeChild PreschoolPneumonia & InfluenzaInfectionCohort studyHumanmedicine.medical_specialtydelayClinical SciencesSars-cov-2GlobalSurg CollaborativeSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciencesClinical ResearchAnesthesiologyBiodefenseCorrespondence617HumansPULMONARY COMPLICATIONSCRIANÇAS EM IDADE PRÉ-ESCOLARAgedScience & TechnologyCirurgiaPreventionCOVID-19; SARS-CoV-2; delay; surgery; timingInfantOdds ratioPneumoniaProspective StudieClinical research/dk/atira/pure/core/keywords/uob_covid19SurgeryHuman medicine610 Medizin und Gesundheit1109 NeurosciencesInternationalitySettore MED/29 - CHIRURGIA MAXILLOFACCIALESettore MED/18 - CHIRURGIA GENERALECOVID-19; delay; SARS-CoV-2; surgery; timing; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Male; Middle Aged; Prospective Studies; SARS-CoV-2; Surgical Procedures Operative; Time; Young Adult; COVID-19; Internationality; Practice Guidelines as TopicgastroenterologyCohort StudiessurgeryMedicine and Health Sciencestiming030212 general & internal medicineProspective cohort studyMortality rateCOVID-19; delay; SARS-CoV-2; surgery; timingCovid19Middle AgedInfectious DiseasesSurgical Procedures OperativePractice Guidelines as TopicFemalePatient Safetymedicine.symptom6.4 SurgeryLife Sciences & BiomedicineAdult61Adolescent610 Medicine & healthCOVID-19 SARS-CoV-2 delay surgery timingAsymptomaticNOCOVIDSurg CollaborativeTimeVaccine RelatedYoung AdultAll institutes and research themes of the Radboud University Medical CentermedicineMortalitatddc:610MortalityPreschoolLS7_4Surgical Proceduresbusiness.industrySARS-CoV-2NeurosciencesEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical Sciences3126 Surgery anesthesiology intensive care radiologySurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Anesthesiology and Pain MedicineEmerging Infectious DiseasesGood Health and Well BeingMortalidadCohort Studiebusiness
researchProduct

Ticks infesting humans in Italy and associated pathogens

2014

Background: Ticks may transmit a large variety of pathogens, which cause illnesses in animals and humans, commonly referred to as to tick-borne diseases (TBDs). The incidence of human TBDs in Italy is underestimated because of poor surveillance and the scant amount of studies available. Methods. Samples (n = 561) were collected from humans in four main geographical areas of Italy (i.e., northwestern, northeastern, southern Italy, and Sicily), which represent a variety of environments. After being morphologically identified, ticks were molecularly tested with selected protocols for the presence of pathogens of the genera Rickettsia, Babesia, Theileria, Candidatus Neoehrlichia mikurensis, Bor…

MaleVeterinary medicineBorrelia valaisianaSettore MED/17 - Malattie InfettiveRhipicephalus sanguineusInfectious DiseaseDistributionBorrelia afzeliimedicine.disease_causeTicksparasitic diseasesmedicineTick-borne diseasesHumansAnimalsTick-borne diseasebiologyPathogenAnimalMedicine (all)ResearchTick-borne diseasebiology.organism_classificationmedicine.diseaseHaemaphysalisbacterial infections and mycosesTick InfestationTick InfestationsRhipicephalusInfectious DiseasesItalyIxodesParasitologyFemaleDistribution; Humans; Italy; Pathogens; Tick-borne diseases; Ticks; Animals; Female; Humans; Italy; Male; Tick Infestations; Ticks; Parasitology; Infectious Diseases; Medicine (all)PathogensDermacentorHumanTick
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

2019

Maleantiretroviral treatmentInfectious Disease TransmissiongenotypeHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeRetrospective StudieGenotypepol Gene Products Human Immunodeficiency ViruPrevalenceMedicineVerticalHIV InfectionViralpol Gene ProductsYoung adultGeneral MedicineInfectious DiseasesItalyMutation (genetic algorithm)FemaleHuman Immunodeficiency VirusHumanMicrobiology (medical)AdultSettore MED/17 - Malattie InfettiveAdolescentAnti-HIV AgentsYoung AdultAcquired resistanceDrug Resistance ViralHumansvertical HIV transmissionAdolescent; Adult; Anti-HIV Agents; Drug Resistance Viral; Female; HIV Infections; HIV-1; Humans; Italy; Male; Mutation; Prevalence; Retrospective Studies; Young Adult; pol Gene Products Human Immunodeficiency Virus; Infectious Disease Transmission VerticalRetrospective StudiesHIV perinatally infectionbusiness.industryAnti-HIV AgentRetrospective cohort studyVirologyInfectious Disease Transmission VerticalLarge cohortpol Gene Products Human Immunodeficiency VirusDrug resistanceMutationHIV-1Drug resistance; HIV-1; antiretroviral treatment; genotype; vertical HIV transmissionbusiness
researchProduct

Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome

2014

Background: Abdominal infections are frequent causes of sepsis and septic shock in the intensive care unit (ICU) and are associated with adverse outcomes. We analyzed the characteristics, treatments and outcome of ICU patients with abdominal infections using data extracted from a one-day point prevalence study, the Extended Prevalence of Infection in the ICU (EPIC) II.Methods: EPIC II included 13,796 adult patients from 1,265 ICUs in 75 countries. Infection was defined using the International Sepsis Forum criteria. Microbiological analyses were performed locally. Participating ICUs provided patient follow-up until hospital discharge or for 60 days.Results: Of the 7,087 infected patients, 1,…

Malehumanoslnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Settore MED/41 - AnestesiologiaGUIDELINESlaw.inventionsepsislawAbdomenabdominal infections; crtitical carePrevalenceMedicine and Health SciencesMedicinePathologie maladies infectieusesAbdomen; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Prevalence; Sepsis; Treatment Outcome; Young Adult; Intensive Care Units; Infectious Diseasesmediana edadMedicine(all)ancianoAbdominal Infection Sepsis Epic IIresultado del tratamientoprevalenciaBacterial InfectionsMiddle AgedadultoAbdominal infectionIntensive care unitAbscessAnti-Bacterial AgentsPREVALENCEadulto jovenIntensive Care UnitsTreatment OutcomeInfectious Diseasesmedicine.anatomical_structureSAPS IIAbdominal infection ; Abscess ; Peritonitis ; Severe sepsis ; Critical care ; Antibiotic therapy ; MicrobiologyFemaleSOFA score10023 Institute of Intensive Care MedicineantibacterianosResearch ArticleAdultmedicine.medical_specialtyCritical Illnessunidades de cuidados intensivosenfermedad críticaPeritonitis610 Medicine & healthNOSOCOMIAL INTRAABDOMINAL INFECTIONSPeritonitisMicrobiologySepsisYoung AdultMORBIDITYInternal medicineMANAGEMENTHumansAgedCANDIDASEPSISbusiness.industrySeptic shockMORTALITYAbdominal InfectionADULTS2725 Infectious DiseasesAntibiotic therapymedicine.diseaseSevere sepsisSurgeryCritical careCross-Sectional Studiesinfecciones bacterianasAbdomenbusinessestudios transversales
researchProduct

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

2020

Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching …

Malelcsh:Diseases of the musculoskeletal systemBiologic:Paediatrics: 760 [VDP]Artritis infecciosaMedDRAInfants malaltsArthritisSeverity of Illness IndexHospital patientsCohort StudiesPharmacovigilance0302 clinical medicine030212 general & internal medicineRegistriesChildBiologics; Immunosuppressive therapy; Infections; Juvenile idiopathic arthritis; Opportunisticbiologics ; immunosuppressive therapy ; infections ; juvenile idiopathic arthritis ; opportunisticBarneleddgikt3. Good healthImmunosuppressive therapySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolCohortPediatric Infectious DiseaseFemaleInfectionResearch Articlemedicine.medical_specialtyTuberculosisjuvenil idiopathic arthritisBiologicsOpportunistic InfectionsInfectionsHerpes Zoster03 medical and health sciencesImmunocompromised HostJuvenile idiopathic arthritiInternal medicinePharmacovigilancemedicineHumansTuberculosisbook030203 arthritis & rheumatologyMalalts hospitalitzatsImmunosupressióbusiness.industrySick childrenJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileInfectious arthritis:Pediatri: 760 [VDP]Orthopedic surgeryOpportunistiske infeksjonerbook.journalOpportunisticlcsh:RC925-935businessInfeccions oportunistesImmunosuppression
researchProduct

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DAL…

2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10-30 mg/L. Thirteen critically ill patients were available for analysis. The followi…

Malevalidityvalidation proceInternational CooperationSettore MED/41 - Anestesiologiadrug protein bindingGastroenterologylaw.inventionPlasmaStaphylococcus infectionCritically ill patientsInterquartile rangelaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAntibioticsantibiotic therapyPharmacology (medical)Pharmacology & PharmacyAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical)Antibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoringclinical articleChromatographymedicine.diagnostic_testdrug dose regimencritical illneTeicoplaninHypoalbuminaemiaMedicine (all)articleGlycopeptidesclinical trialGeneral MedicineMiddle Agedtrough time concentrationdrug protein binding variabilityIntensive care unitGlycopeptides Antibiotics Critically ill patients Pharmacokinetics Hypoalbuminaemia ICU3. Good healthAnti-Bacterial Agentsantiinfective agentdrug distributionInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journalmulticenter study (topic)Vancomycinblood samplingFemaleCritically ill patientDrug MonitoringHumanmedicine.drugProtein BindingMicrobiology (medical)Adultmedicine.medical_specialtyhigh performance liquid chromatographyarea under the curveCritical Illnessultraviolet spectroscopymid dose concentrationchemistryGlycopeptideMicrobiologyteicoplanin adultenterococcal infectionyoung adult Adultdrug clearanceYoung AdultTherapeutic indexPharmacokineticsInternal medicineAnti-Bacterial AgentmedicineHumanssteady statePharmacokineticsDosingAgedbusiness.industrydrug half lifeAntibioticrecommended drug doseAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical); Medicine (all)calibrationSurgerymulticenter studyTherapeutic drug monitoringdrug blood levelICU[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyfree plasma drug concentrationTeicoplaninbusinessmetabolism
researchProduct

Cilvēka lipīgo slimību mikrobioloģija ar imunitātes mācību: bijušā Latvijas Universitātes profesora Dr. med. E. Fērmaņa lekcijas LU Medicīnas fakultā…

1940

Medicīniskā mikrobioloģijaMikrobioloģija:MEDICINE::Microbiology immunology infectious diseases [Research Subject Categories]ImunitāteEpidemioloģijaInfekcijas slimībasMedicīna
researchProduct

Healthcare-Associated Pneumonia and Multidrug Resistant Bacteria: Do We Have a Convincing Answer?

2014

Methicillin-Resistant Staphylococcus aureusMicrobiology (medical)medicine.medical_specialtyBacteriabusiness.industryMedicine (all)Drug ResistanceBacterialPneumonia Ventilator-AssociatedBacteria; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia Ventilator-Associated; Pseudomonas aeruginosa; Drug Resistance Bacterial; Infectious Diseases; Microbiology (medical); Medicine (all)Pneumoniamedicine.diseasePneumoniaVentilator-AssociatedMultidrug resistant bacteriaInfectious DiseasesHealthcare associatedEnterobacteriaceaeDrug Resistance BacterialPseudomonas aeruginosamedicineBacteria; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Ventilator-Associated; Pseudomonas aeruginosa; Drug Resistance; Bacterial; Infectious Diseases; Microbiology (medical); Medicine (all)HumansIntensive care medicinebusiness
researchProduct